Contact Us

CleanCap® Reagent AG (3' OMe) - (N-7413)

CleanCap®Reagent AG (3' OMe) for co-transcriptional capping of mRNA, m7(3'OMeG)(5')ppp(5')(2'OMeA)pG
In stock
default
N-7413
Product SKU Quality Grade Unit Size Price Qty
N-7413
N-7413-1 RUO 1 µmole
$132.00
N-7413-5 RUO 5 µmole
$633.00
N-7413-10 RUO 10 µmole
$1,190.00
N-7413-100 RUO 100 µmole
$9,712.00
FN-7413-1mmol GMP 1 mmol Inquire
FN-7413-10mmol GMP 10 mmol Inquire
 
Description

TriLink's patented CleanCap® Reagent AG (3' OMe) is a co-transcriptional capping reagent for in vitro transcription of 5’ capped mRNA resulting in a Cap 1 structure with up to 98% capping efficiency.

CleanCap Reagent AG (3' OMe) includes the 5' N7-Methyl-3'-O-Methylguanosine commonly found in mRNA capped using ARCA, whereas CleanCap Reagent AG has a naturally occurring 5' N7-Methylguanosine structure.

PLEASE NOTE: CleanCap Reagent AG and CleanCap Reagent AG (3’ OMe) require an AG initiator. To learn more, please review the Product Insert below.

TriLink's patented CleanCap reagents are available in “Research Use” grade as well as GMP-grade “For Further Processing.” GMP product is manufactured in accordance with ISO 9001:2015 and Quality Standards as defined in a GMP Quality Agreement.

To learn more visit: https://www.trilinkbiotech.com/gmp-reagents

Product details
Catalog No N-7413
Purity ≥95% by AX-HPLC
Extinction Coefficient 30,539 Lmol-1cm-1 at 255 nm
Molecular Formula C33H45N15O24P4 (free acid)
Molecular Weight 1159.60
Salt Form Na+
Concentration 100 mM
Buffer H2O
Recommended Storage -20°C or below
Other Name(s) CleanCap®Reagent AG (3' OMe) for co-transcriptional capping of mRNA, m7(3'OMeG)(5')ppp(5')(2'OMeA)pG
Application CRISPR, In vitro Transcription, Recombinases, TALENS, Transposases, Vaccine Development, Zinc Finger Nucleases
Backbone 5'-5'-Triphosphate
Base Analog(s) Adenosine, Guanosine
Nucleotide Category Cap analogs
Cap Analogs CleanCap Cap Analogs
Technical documents

Safety Data Sheet Look-up

CleanCap AG (3'OMe) Reagent (N-7413) Product Insert

Products FAQs

Ask an Expert

Certificate of analysis

CoA search tool

Intellectual property

CleanCap capping technology For Research Use Only. Not for use in humans. Not for use in diagnostic or therapeutic purposes. For additional licensing restrictions, please see the license agreement at trilinkbiotech.com/cleancap-research-license. Patents and patent pending, see trilinkbiotech.com/legal-notices.

Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission from TriLink No license under any patent or other intellectual property right of TriLink or its licensors is granted or implied by the purchase unless otherwise provided in writing.

TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.

References
  1. Rothgangl, T;Dennis, MK;Lin, PJC;Oka, R;Witzigmann, D;Villiger, L;Qi, W;Hruzova, M;Kissling, L;Lenggenhager, D;Borrelli, C;Egli, S;Frey, N;Bakker, N;Walker, JA;Kadina, AP;Victorov, DV;Pacesa, M;Kreutzer, S;Kontarakis, Z;Moor, A;Jinek, M;Weissman, D;Stoffel, M;van Boxtel, R;Holden, K;Pardi, N;Th . In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
  2. Weissman, D;Alameh, MG;de Silva, T;Collini, P;Hornsby, H;Brown, R;LaBranche, CC;Edwards, RJ;Sutherland, L;Santra, S;Mansouri, K;Gobeil, S;McDanal, C;Pardi, N;Hengartner, N;Lin, PJC;Tam, Y;Shaw, PA;Lewis, MG;Boesler, C;?ahin, U;Acharya, P;Haynes, BF;Korber, B;Montefiori, DC; . D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
  3. Pandey, RR;Delfino, E;Homolka, D;Roithova, A;Chen, KM;Li, L;Franco, G;V . The Mammalian Cap-Specific m6Am RNA Methyltransferase PCIF1 Regulates Transcript Levels in Mouse Tissues
  4. Ouranidis, A;Davidopoulou, C;Tashi, RK;Kachrimanis, K; . Pharma 4.0 Continuous mRNA Drug Products Manufacturing
  5. Mu, Z;Wiehe, K;Saunders, KO;Henderson, R;Cain, DW;Parks, R;Martik, D;Mansouri, K;Edwards, RJ;Newman, A;Lu, X;Xia, SM;Bonsignori, M;Montefiori, D;Han, Q;Venkatayogi, S;Evangelous, T;Wang, Y;Rountree, W;Tam, Y;Barbosa, C;Munir Alam, S;Williams, WB;Pardi, N;Weissman, D;Haynes, BF; . Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles
  6. Martinez, DR;Schaefer, A;Leist, SR;De la Cruz, G;West, A;Atochina-Vasserman, EN;Parks, R;Barr, M;Li, D;Yount, B;Saunders, KO;Weissman, D;Haynes, BF;Montgomery, SA;Baric, RS; . Chimeric spike mRNA vaccines protect against sarbecovirus challenge in mice
  7. Alameh, MG;Tomb . Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses
Show more